BioNTech Acquires Chinese Oncology Firm Biotheus for $950M

The Care and Protection of Children Trust

CPCT Launches Groundbreaking Initiative to Provide Lifelong Free Treatment for Children with Spinal Muscular Atrophy (SMA) in Karnataka

Early Comprehensive Genomic Profiling Improves Cancer Treatment Outcomes, Study Shows

EMA Reverses Decision, Recommends Limited Approval for Eisai and Biogen’s Alzheimer’s Drug Leqembi

Exact Sciences Unveils Advances in Multi-Cancer Early Detection with Cancerguard™ Test

MSD and LaNova Medicines Enter Exclusive Global License Agreement for Novel Cancer Therapy, LM-299

Promising CAR T Cell Therapies from BMS and Cabaletta Bio Show Potential for Durable Remission in Severe Lupus

FDA Grants Accelerated Approval to PTC Therapeutics' KEBILIDI™, the First Gene Therapy for AADC Deficiency in the U.S.

Association for Molecular Pathology Publishes Joint Consensus Report on SARS-CoV-2 Genomic Surveillance for Hospitals and Public Health Laboratories

Philips India Unveils Advanced Azurion Imaging System to Revolutionize Cardiac and Neurovascular Care

Tempus AI Study Highlights Benefits of Dual RNA and DNA Sequencing for Advanced Lung Cancer

Ontada and Datavant Partner to Expand Access to Real-World Oncology Data for Accelerated Cancer Innovation

Tempus AI and Flatiron Health Partner to Integrate Genomic Testing into OncoEMR for Enhanced Oncology Care

Flare Therapeutics and Roche Forge Strategic Partnership to Discover Precision Oncology Therapies Targeting Transcription Factors

FDA Approves Autolus’s CAR-T Therapy Aucatzyl for Relapsed or Refractory B-ALL in Adults

Home
/
update
/
details

MedGenome and Twist Bioscience Partner to Launch HOPE for Rare Diseases Programme in India

NextEdge Admin

26 Sep 2024

1 min 55 sec

Twist Bioscience,Rare Diseases,partnership

MedGenome, a leading global genomics diagnostics and research company, has partnered with US-based Twist Bioscience to launch the HOPE for Rare Diseases Programme in India. This initiative offers discounted whole exome sequencing to economically disadvantaged patients, marking a milestone in MedGenome’s decade of genomics advancements. The programme aims to democratize access to affordable genetic solutions, addressing the unmet healthcare needs in emerging markets.

Twist Bioscience supports the initiative by providing its advanced Twist Exome 2.0, a tool designed to detect rare diseases and germline cancers. Despite its availability for over a decade, whole exome sequencing has been underutilized due to high costs, limited awareness, and the lack of insurance coverage in India’s out-of-pocket healthcare system. The HOPE Programme, launched in August 2024, seeks to overcome these barriers by offering affordable sequencing for rare disease patients.

Rare genetic diseases, while individually uncommon, collectively affect over 70 million people in India, many of them children. Whole exome sequencing helps clinicians identify genetic variants responsible for these diseases, expediting diagnoses and guiding treatment options, potentially ending patients’ long diagnostic journeys. This partnership aims to make critical genetic information accessible to the underserved, improving care and management.